Craig-Hallum downgraded Akoya Biosciences (AKYA) to Hold from Buy with a price target of $5, down from $7, citing increased concerns about macro level demand and a lack of visibility following the company’s Q3 report. While the firm’s near-term outlook is “more tepid,” it continues to see value over time, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences price target lowered to $3.50 from $6 at Canaccord
- Akoya Biosciences Reports Q3 2024 Financial Results
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
- Akoya Biosciences reports Q3 EPS (21c), consensus (20c)
- Akoya Biosciences lowers FY24 revenue view to $80M-$85M, consensus $98.19M